The Retatrutide pen (often called a Reta Pen) is a research-only format of retatrutide, supplied in solution and filled fresh to order in 20mg and 40mg cartridge strengths. It is the same compound as our Retatrutide research vials, presented in a pen-format container instead of as a freeze-dried powder. For in-vitro laboratory research use only. Not for human or veterinary use.
The certificate that accompanies the pen is the source-batch COA for the lyophilised 20mg or 40mg batch the cartridge is prepared from. The pen solution itself is not separately tested. You can open the batch documents on our verification page. You can also see the peptide pens range, the pens UK guide, the Buy Retatrutide UK page, and the Learning Hub.
About the Retatrutide Pen (Reta Pen)
Retatrutide Pen is available in 20mg and 40mg strengths of retatrutide supplied in solution, filled fresh to order, in a pen-format container instead of as a freeze-dried powder in a standard vial. The compound is the same as our Retatrutide research peptide; see that page for full details of the compound and the published research.
Retatrutide (development code LY3437943) is an investigational synthetic peptide of 39 amino acids with an attached fatty-acid side chain. It acts at three hormone receptors: the glucagon receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor [1]. It has the molecular formula C221H342N46O68 and a molecular weight of approximately 4731 g/mol.
Retatrutide has not been approved as a medicine by the MHRA, the FDA or any other regulator. The product sold here is a research compound for laboratory use only. The pen format describes the container only.
What is in the Retatrutide pen (Reta Pen)?
Each Reta Pen is filled fresh to order with retatrutide in solution, in the 20mg or 40mg strength you select. The compound is the same as the matching lyophilised Retatrutide vial. Format, molecular formula and purity figures stay in the specifications table already on this page. Purity figures come from the source-batch COA, not from a separate test of the filled cartridge. View the batch COA.
What’s in the Retatrutide Pen (Reta Pen) kit?
Each Retatrutide Pen (Reta Pen) kit is filled fresh to order, sealed and boxed, and includes a hard case. Choose 20mg (£124.99) or 40mg (£159.99). Multi-pen basket savings (Buy 2 Save £10 · Buy 3+ Save £25) can be mixed across 20mg and 40mg kits. Those savings do not apply to Refill Pens.
If you already have a kit, a Retatrutide 20mg Refill Pen (£104.99) or Retatrutide 40mg Refill Pen (£139.99) is the pen only plus 6 new needles, with no hard case or box. Filled fresh to order from the same source batch.
Storage for laboratory handling
Keep the pen refrigerated at 2–8 °C, sealed and away from light. Do not freeze it. A solution keeps for less time than dry powder. Use within 30 to 45 days after first use of the pen. Handle only in a suitable laboratory, following your institution’s safety procedures.
UK preparation and delivery
Pens made from in-stock compounds take 2 days to prepare and label before dispatch, then go out by Royal Mail Tracked 24 (next working day).
Refill Pens (pen only)
Already have a Retatrutide Pen (Reta Pen) kit? A Refill Pen is the pen only plus 6 new needles, with no hard case or box: Retatrutide 20mg Refill Pen (£104.99) and Retatrutide 40mg Refill Pen (£139.99). Filled fresh to order from the same source batch. Multi-pen basket savings do not apply to Refill Pens. For in-vitro laboratory research use only.
Pen or vial for laboratory work?
Choose the Reta Pen when a ready-made solution in a sealed cartridge suits the protocol. Choose a lyophilised Retatrutide vial when the work starts from dry powder. A longer comparison of cartridge and vial handling is in our pens vs lyophilised vials guide. All formats are for in-vitro laboratory research only.
For the structure of the compound, see Retatrutide structure: sequence, Aib residues and the fatty-acid chain. For the three receptors named in the specifications, see GLP-1, GIP and glucagon receptor peptides. To check a certificate, use How to verify a peptide COA (UK) and Reading an HPLC chromatogram. Further background sits in the Learning Hub and in Laboratory testing explained.
FAQ
What is a Reta Pen?
“Reta Pen” is a short name for a Retatrutide pen: retatrutide supplied in solution in a pen-format research container. It is not a licensed medicine.
Is the COA for the filled pen?
No. The COA is for the source lyophilised batch the pen is prepared from. On Lingda reports the Client is the manufacturer/supplier; we publish the file exactly as issued. The filled solution is not separately tested. See the verification page.
Does Corex hold these as ready-made stock?
No. Each Retatrutide pen is filled fresh to order from in-stock lyophilised compound, then labelled for sale.
Can I also see the vial format?
Yes. The same compound is listed as a lyophilised vial on the Retatrutide product page and in the Buy Retatrutide UK guide.
What comes with the Retatrutide Pen (Reta Pen) kit?
The kit is filled fresh to order, sealed and boxed, and includes a hard case, in 20mg or 40mg. A Refill Pen is the pen only plus 6 new needles, with no hard case or box.
Which strengths are listed?
This page lists a 20mg Reta Pen at £124.99 and a 40mg Reta Pen at £159.99. Both are filled fresh to order.
Areas of research
Retatrutide is in clinical development. Published research includes:
- structural studies of how this single molecule binds to and activates all three receptors [1]
- studies of its effects on isolated mouse heart (atrial) tissue [2]
- a laboratory LC-HRMS method that identifies and measures retatrutide alongside other GLP-1 receptor agonists [3]
These are clinical studies of an investigational compound, cited for scientific background only.
Product specifications
| Format |
Solution in a pen-format container, filled fresh to order |
| Contents |
Retatrutide, 20mg or 40mg (per selected option) |
| Molecular formula |
C221H342N46O68 |
| Molecular weight |
approx. 4731 g/mol |
| Purity |
See the COA. Current 20mg and 40mg COAs report HPLC purity above 99.7% (20mg batch LDA22160902: >99.76%; 40mg batch LDA22160922: >99.76%). |
Storage and handling
Storage & Handling — Corex Vitality™ research vials
- Filled fresh to order as a solution, not powder. Keep refrigerated at 2–8 °C, sealed and away from light.
- Do not freeze.
- A solution keeps far less well than dry powder. Use within 30 to 45 days after first use of the pen.
- Handle only in a suitable laboratory setting, following your institution’s safety procedures. Keep out of reach of children.
For in-vitro laboratory research use only. Not for human or veterinary use. General guidance paraphrased from Bachem: Handling and Storage Guidelines for Peptides and Peptide Solubility.
Quality and testing
The COA shown is for the source lyophilised Retatrutide batch (20mg or 40mg) that the pen is prepared from. Purity figures come from that lyophilised batch COA (current published listings: 20mg batch LDA22160902, HPLC purity >99.76% ± 0.18%; 40mg batch LDA22160922, HPLC purity >99.76% ± 0.18%). On Lingda reports the Client is the manufacturer/supplier, not Corex Vitality™; we publish the file exactly as issued. The pen solution itself is not separately tested. You can open the documents on our COA and verification page.
Research use only
For in-vitro laboratory research use only. Not for human or veterinary use. These products are research chemicals. They are not medicines, food, or supplements. They have not been evaluated by the MHRA, FDA, or any other regulatory body. Not intended to diagnose, treat, cure, or prevent any disease. All descriptions are for reference and research documentation purposes only. By purchasing, you confirm you are aged 18+ and using these products exclusively for in vitro laboratory research.
Related reading
References
- Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024. PubMed 39019866
- Neumann J, et al. Contractile effects of retatrutide in isolated mouse atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 2025. PubMed 40464942
- Tong LH, et al. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. J Chromatogr A. 2026. PubMed 42603384
Reviews
There are no reviews yet.